
Clinical research indicates that 90% of Conformis iTotal PS patients studied in peer-reviewed clinical research were satisfied, or very satisfied, at 18 to 28 months following their knee replacement surgery. Further, 88% of patients reported that their knees felt natural either some or all of the time.
Implant survivorship was found to be 100% at an average of 23 months post-op for the 100 knees included in the study.
The clinical study tested the hypothesis that the total knee replacement device would drive high overall patient-reported outcomes because of its patient-specific design.
“This peer-reviewed clinical research is the latest in more than thirty studies published in medical journals that supports the strong performance of our patient-specific implants, which are designed to fit each patient’s unique anatomy,” said Mark Augusti, President and Chief Executive Officer.
“While market research generally indicates that knee replacement with traditional knee implants fails to satisfy 20% to 30% of patients, we are pleased to once again see that our technology is a major contributor to much higher patient satisfaction, an end to chronic pain, and restoration of mobility.”
Clinical research indicates that 90% of Conformis iTotal PS patients studied in peer-reviewed clinical research were satisfied, or very satisfied, at 18 to 28 months following their knee replacement surgery. Further, 88% of patients reported that their knees felt natural either some or all of the time.
Implant survivorship was found to be 100%...
Clinical research indicates that 90% of Conformis iTotal PS patients studied in peer-reviewed clinical research were satisfied, or very satisfied, at 18 to 28 months following their knee replacement surgery. Further, 88% of patients reported that their knees felt natural either some or all of the time.
Implant survivorship was found to be 100% at an average of 23 months post-op for the 100 knees included in the study.
The clinical study tested the hypothesis that the total knee replacement device would drive high overall patient-reported outcomes because of its patient-specific design.
“This peer-reviewed clinical research is the latest in more than thirty studies published in medical journals that supports the strong performance of our patient-specific implants, which are designed to fit each patient’s unique anatomy,” said Mark Augusti, President and Chief Executive Officer.
“While market research generally indicates that knee replacement with traditional knee implants fails to satisfy 20% to 30% of patients, we are pleased to once again see that our technology is a major contributor to much higher patient satisfaction, an end to chronic pain, and restoration of mobility.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.